Twist Bioscience Corporation (TWST)
收市後：
Twist Bioscience Corporation
681 Gateway Boulevard
South San Francisco, CA 94080
United States
800 719 0671
https://www.twistbioscience.com
版塊: Healthcare
行業: Diagnostics & Research
全職員工: 919
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Emily Marine Leproust Ph.D. | Co-Founder, Chairman & CEO | 1.37M | 153.71k | 1973 |
| Dr. Patrick John Finn Ph.D. | President & COO | 943.94k | 無 | 1972 |
| Ms. Paula Green | Senior Vice President of Human Resources | 618.48k | 無 | 1968 |
| Dr. William Charles Banyai Ph.D. | Senior VP of Advanced Development, GM of Data Storage & Director | 711.34k | 無 | 1955 |
| Mr. Adam Laponis | Chief Financial Officer | 無 | 無 | 1977 |
| Mr. Robert F. Werner | VP & Chief Accounting Officer | 無 | 無 | 1973 |
| Mr. Siyuan Chen | Chief Technology Officer | 無 | 無 | 無 |
| Dr. Aaron K. Sato Ph.D. | Chief Scientific Officer | 無 | 無 | 無 |
| Mr. Chet Gandhi | Chief Information Officer | 無 | 無 | 無 |
| Mr. Dennis Cho | Senior VP, Chief Legal Officer & Corporate Secretary | 537.93k | 無 | 1971 |
描述
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
公司管治
截至 2024年4月1日 止，Twist Bioscience Corporation 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：8；董事會：8；股東權利：7；現金賠償：5。
